- 2024.01.08
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2024.03.14
The Company announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.
2024.02.07
The agreement marks an important milestone to advance the Company’s intent to become a U.S.-based biotech.
2023.11.06
The Company will have presentations and one-to-one meetings during the upcoming two investor conferences.
Events